EASE OF USE OF TIRZEPATIDE: RESULTS FROM A US SURVEY OF INDIVIDUALS WITH OBESITY OR OVERWEIGHT
Author(s)
Theresa Hunter, MPH, MS, PhD1, Elizabeth Collins, MA2, Claire Gerber, PharmD3, Catherine Bottomley, PhD4, Michael Shepherd, PharmD5, Xuanyao He, PhD5, Angela Golden, MD6, Harold Bays, MD7;
1Eli Lilly and Company, Medical Affairs HEOR, Indianapolis, IN, USA, 2Clarivate, Edinburgh, United Kingdom, 3Eli Lilly & Company, Medical Affairs, Indianapolis, IN, USA, 4Clarivate Analytics, London, United Kingdom, 5Eli Lilly & Company, Indianapolis, IN, USA, 6Obesity Society, Rockville, MD, USA, 7Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
1Eli Lilly and Company, Medical Affairs HEOR, Indianapolis, IN, USA, 2Clarivate, Edinburgh, United Kingdom, 3Eli Lilly & Company, Medical Affairs, Indianapolis, IN, USA, 4Clarivate Analytics, London, United Kingdom, 5Eli Lilly & Company, Indianapolis, IN, USA, 6Obesity Society, Rockville, MD, USA, 7Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
OBJECTIVES: This study assessed how easily and confidently individuals administered tirzepatide for obesity or overweight.
METHODS: This descriptive analysis evaluated baseline data of full-time employees without T2D who initiated tirzepatide for obesity/overweight. Data were derived from a US longitudinal survey conducted June-November 2025 among obesity medication (OM)-eligible (BMI ≥30 kg/m2, or 27-29.9 kg/m2 with ≥1 obesity-related complication) individuals. Participants completed the modified Subcutaneous Administration Assessment Questionnaire (SQAAQ), which includes 12 items scored on a 7-point Likert scale, specifying agreement/disagreement.
RESULTS: The analysis included 518 participants. The majority were female (78.2%), White (69.5%), mean age of 46.0 years, and mean BMI of 38.4 kg/m2 (SD 8.4). At the time of tirzepatide initiation, 67.8% (n=351) used tirzepatide autoinjector pens and 32.2% (n=167) used tirzepatide vials. The majority (98.0%) of autoinjector and vial (95.8%) users stated that tirzepatide was “overall easy to use”. Similarly, 96.3% of autoinjector users stated that the pen was “easy for them to unlock”, 97.4% reported that it was “easy to inject their dose”, and 94.3% reported that is “easy for them to know their dose is complete”. Additionally, 89.2% of vial users reported that it was “easy for them to inject their dose” and 91.6% reported that it was “easy for them to know their dose was complete”. 97.6% of autoinjector and 97.0% of vial users stated that tirzepatide was “easy for them to store in their refrigerator”. Finally, 97.5% of autoinjector and 89.2% of vial users report that they were “confident in their ability to use the dose” and 95.2% of autoinjectors and 93.4% of vial users reported that they were “confident that their dose is complete”.
CONCLUSIONS: In this real-world survey, most tirzepatide autoinjector and vial users reported that tirzepatide was easy to use and that they were confident in administering their dose.
METHODS: This descriptive analysis evaluated baseline data of full-time employees without T2D who initiated tirzepatide for obesity/overweight. Data were derived from a US longitudinal survey conducted June-November 2025 among obesity medication (OM)-eligible (BMI ≥30 kg/m2, or 27-29.9 kg/m2 with ≥1 obesity-related complication) individuals. Participants completed the modified Subcutaneous Administration Assessment Questionnaire (SQAAQ), which includes 12 items scored on a 7-point Likert scale, specifying agreement/disagreement.
RESULTS: The analysis included 518 participants. The majority were female (78.2%), White (69.5%), mean age of 46.0 years, and mean BMI of 38.4 kg/m2 (SD 8.4). At the time of tirzepatide initiation, 67.8% (n=351) used tirzepatide autoinjector pens and 32.2% (n=167) used tirzepatide vials. The majority (98.0%) of autoinjector and vial (95.8%) users stated that tirzepatide was “overall easy to use”. Similarly, 96.3% of autoinjector users stated that the pen was “easy for them to unlock”, 97.4% reported that it was “easy to inject their dose”, and 94.3% reported that is “easy for them to know their dose is complete”. Additionally, 89.2% of vial users reported that it was “easy for them to inject their dose” and 91.6% reported that it was “easy for them to know their dose was complete”. 97.6% of autoinjector and 97.0% of vial users stated that tirzepatide was “easy for them to store in their refrigerator”. Finally, 97.5% of autoinjector and 89.2% of vial users report that they were “confident in their ability to use the dose” and 95.2% of autoinjectors and 93.4% of vial users reported that they were “confident that their dose is complete”.
CONCLUSIONS: In this real-world survey, most tirzepatide autoinjector and vial users reported that tirzepatide was easy to use and that they were confident in administering their dose.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR5
Topic
Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives, Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)